par Awada, Ahmad
;Thödtmann, R;Piccart-Gebhart, Martine
;Wanders, Jantien;Schrijvers, A H G J;Von Broen, I-M;Hanauske, Axel-R;EORTC-ECSG phase I study,
Référence European journal of cancer, 39, 6, page (742-747)
Publication Publié, 2003-04


Référence European journal of cancer, 39, 6, page (742-747)
Publication Publié, 2003-04
Article révisé par les pairs
Titre: |
|
Auteur: | Awada, Ahmad; Thödtmann, R; Piccart-Gebhart, Martine; Wanders, Jantien; Schrijvers, A H G J; Von Broen, I-M; Hanauske, Axel-R; EORTC-ECSG phase I study, |
Informations sur la publication: | European journal of cancer, 39, 6, page (742-747) |
Statut de publication: | Publié, 2003-04 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Aged | |
Amides -- administration & dosage | |
Amides -- adverse effects | |
Amides -- pharmacokinetics | |
Antineoplastic Agents -- administration & dosage | |
Antineoplastic Agents -- adverse effects | |
Antineoplastic Agents -- pharmacokinetics | |
Cohort Studies | |
Drug Administration Schedule | |
Female | |
Half-Life | |
Humans | |
Infusions, Intravenous | |
Isoquinolines -- administration & dosage | |
Isoquinolines -- adverse effects | |
Isoquinolines -- pharmacokinetics | |
Male | |
Maximum Tolerated Dose | |
Middle Aged | |
Neoplasms -- drug therapy | |
Note générale: | Clinical Trial |
Clinical Trial, Phase I | |
Journal Article | |
Langue: | Anglais |
Identificateurs: | urn:issn:0959-8049 |
info:pii/S0959804902007761 | |
info:pmid/12651198 |